1 September 2024

Starpharma presents at ASX Small and Mid-Cap Conference (ASX Announcement)

 

Melbourne, Australia; 22 March 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) announces that Starpharma CEO Dr Jackie Fairley will present a brief overview of the Company at the ASX Small and Mid-Cap Conference today at 11:00am AEDT. The Conference showcases selected ASX-listed companies to Australian investors.

Starpharma’s presentation will include a brief overview of its portfolio, key value drivers and outlook, including:

  • the Company’s clinical-stage DEP® programs;
  • multiple DEP® partnerships with global companies;
  • new AZD0466 data, including preclinical data in small cell lung cancer (SCLC) and clinical data in Phase 1 solid-tumour patients, which will be presented by AstraZeneca at the upcoming American Association for Cancer Research Annual Meeting in April 2023; and
  • on-market products including VIRALEZE™ and VivaGel®

Investors are invited to join the Conference by registering online at:  https://www2.asx.com.au/
investors/investment-tools-and-resources/events/smid

The presentation can be viewed here. 

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.